A Phase 3 interventional study of Chloroprocaine 3% eye gel and Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops in Local Anesthetic, sponsored by Sintetica SA. Completed at 3 sites in Italy. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by Sintetica SA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to assess the efficacy and safety of Chloroprocaine 3% eye gel compared to Oxybuprocaine 0,4% eye drops when used for inducing ocular surface anesthesia in pediatric patients.
74 Participants (male and female, aged 0-17 yrs) will be 1:1 randomized for receiving either the test drug (Chloroprocaine) or the reference drug (Oxybuprocaine) before undergoing to ocular exam who needs ocular surface anesthesia.
The successful surface anesthesia will be evaluated 5 minutes after receiving 2 drops (1 minute apart) of either test or reference drug by an eye spear sponge
Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be enrolled in this study, patients must fulfil all these inclusion criteria:
Female subjects currently either of:
Exclusion Criteria:
Ophthalmic exclusion criteria
History of ocular traumatism, infection or inflammation within the last 3 months Systemic/non ophthalmic exclusion criteria
Any other medical or surgical history, disorder or disease such as acute or chronic severe organic disease: hepatic, endocrine neoplasia, hematological diseases, severe psychiatric illness, cardiac rhythm disorders and/or any complicating factor or structural abnormality judged by the investigator to be incompatible with the study
NOT ALLOWED CONCOMITANT MEDICATIONS (washout times) Any change in concomitant anti-depressant medication: no changes permitted during the entire trial duration Any topical ocular treatment: within 15 days before inclusion Systemic opioids and morphine drugs, Sulohonamides, Anticholinesterase drugs: from 15 day before the inclusion visit onwards Any change in other systemic medication already ongoing before the inclusion visit: 7 days before the inclusion visit onwards Other systemic antalgics drugs (except for paracetamol)* from Day 1 onwards
*Paracetamol after primary endpoint assessment and oral, implantable, transdermal, or injectable for girls during the entire study will be allowed
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The assigned investigational product (2 drops) will be instilled in both eyes of each subject. Administrations will be performed at the clinical centre by the Investigator or his/her deputy on study day 1. For each administration, the 2 drops will be instilled one at the time, at a 1 min interval.
Drug: Chloroprocaine 3% eye gel
The assigned active comparator (2 drops) will be instilled in both eyes of each subject. Administrations will be performed at the clinical centre by the Investigator or his/her deputy on study day 1. For each administration, the 2 drops will be instilled one at the time, at a 1 min interval.
Drug: Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops
ocular surface anesthesia
Also known as: Chemical Abstracts Service (CAS) nr 3858-89-7
Drug page: Benoxinate
ocular surface anesthesia
Also known as: Benoxinate
Conjunctiva Anesthesia With Chloroprocaine 3% Eye Gel as Compared With Oxybuprocaine Chlorhydrate 0.4% Eye Drops
Efficacy outcome: assess of patients in each treatment group with a successful conjunctiva anesthesia in the right eye, 5 minutes after study product administration, i.e. right before the ocular examination, to be assessed by eye spear sponge.
Time frame: day 1
Number of Participants With Adverse Events
Evaluation of safety by assessing the occurrence of adverse events throughout the study
Time frame: from day 1 until study end (day 8 or day 15)
Assessing the Product Global Tolerance Graded
Evaluation of safety by assessing the product global tolerance graded by the Investigator by answering the following question "How do you consider the study product global tolerance" using the following scale: 0=very unsatisfactory, 1=unsatisfactory, 2= satisfactory, 3=very satisfactory.
Time frame: day 1, post dose
| Milestone | Chloroprocaine 3% Gel | Oxybuprocaine 0,4% Solution |
|---|---|---|
| Started | 38 | 36 |
| Completed | 37 | 36 |
| Not completed | 1 | 0 |
Efficacy outcome: assess of patients in each treatment group with a successful conjunctiva anesthesia in the right eye, 5 minutes after study product administration, i.e. right before the ocular examination, to be assessed by eye spear sponge.
| participants | Chloroprocaine 3% Gel | Oxybuprocaine 0,4% Solution |
|---|---|---|
| Conjunctiva Anesthesia With Chloroprocaine 3% Eye Gel as Compared With Oxybuprocaine Chlorhydrate 0.4% Eye Drops | 19 | 23 |
Evaluation of safety by assessing the occurrence of adverse events throughout the study
| Participants | Chloroprocaine 3% Gel | Oxybuprocaine 0,4% Solution |
|---|---|---|
| Number of Participants With Adverse Events | 1 | 0 |
Evaluation of safety by assessing the product global tolerance graded by the Investigator by answering the following question "How do you consider the study product global tolerance" using the following scale: 0=very unsatisfactory, 1=unsatisfactory, 2= satisfactory, 3=very satisfactory.
| Participants | Chloroprocaine 3% Gel | Oxybuprocaine 0,4% Solution |
|---|---|---|
| Scores 3 | 25 | 27 |
| Scores 2 | 10 | 7 |
| Scores 1 | 0 | 0 |
| Score 0 | 1 | 2 |
| Not done | 1 | 0 |
Collected over 18 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chloroprocaine 3% Gel | 0/37 (0%) | 0/37 (0%) | 1/37 (2.7%) |
| Oxybuprocaine 0,4% Solution | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Event | Chloroprocaine 3% Gel | Oxybuprocaine 0,4% Solution |
|---|---|---|
| eye pruritusEye disorders | 1/37 | 0/36 |
| Injury cornealEye disorders | 1/37 | 0/36 |
| Age, Categorical(Participants) | Chloroprocaine 3% Gel | Oxybuprocaine 0,4% Solution | Total |
|---|---|---|---|
| <=18 years | 37 | 36 | 73 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Chloroprocaine 3% Gel | Oxybuprocaine 0,4% Solution | Total |
|---|---|---|---|
| Female | 14 | 12 | 26 |
| Male | 23 | 24 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Chloroprocaine 3% Gel | Oxybuprocaine 0,4% Solution | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 6 |
| Not Hispanic or Latino | 33 | 32 | 65 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2024 to primary completion in Mar 2025, 9 months.
Results were first posted in Mar 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chloroprocaine
Sintetica SA